The FGFR1–3 inhibitor named AZD4547 was tested in a phase II clinical trial in patients with advanced tumors, including HER2-negative breast cancer, non-small cell lung cancer, and gastroesophageal carcinomas harboring FGFR1/2 amplification. This evidence concerns the gene ERBB2 and breast cancer.